Publication de 12 numéros par an
ISSN Imprimer: 1521-9437
ISSN En ligne: 1940-4344
Indexed in
Immunomodulation and Antitumor Activity of a Mushroom Product, Proflamin, Isolated from Flammulina velutipes (W. Curt.: Fr.) Singer (Agaricomycetideae)
RÉSUMÉ
Proflamin (PRF), an antitumor agent, is orally effective against the syngeneic tumor in mice and is a biological response modifier obtained from an edible mushroom. It has been isolated from the mycelia of Flammulina velutipes (W. Curt.: Fr.) Singer and is an acidic glycoprotein containing more than 90% protein and less than 10% carbohydrate; its molecular weight is 13,000 ± 4000. PRF greatly increases the lifespan of mice implanted with the syngeneic tumors, B-16 melanoma and adenocarcinoma 755 and inhibits the growth of solid tumors of Sarcoma 180 (S-180) by so-called "host-mediated" antitumor activities. PRF inhibited the growth of S-180 or L1210 leukemia ascite cells in combination with the S-180 solubilized vaccine or glutaraldehyde and Con A-bound L1210 vaccine and showed strong antitumor activity when a combination therapy was given with surgical treatment in mice bearing Meth-A fibrosarcoma (Meth-A). The combination therapy with cryosurgery and PRF was found to abolish the suppression of tumor immunocompetence at 2 weeks after cryosurgery, and it exhibited no toxic actions either in vitro or in vivo. Oral administration of PRF significantly intensified various immunoresponses in tumor-bearing mice, but it was not very effective against the immunity of healthy (non-tumor-bearing) mice. The effective dose range for immunomodulation was rather wide (1−30 mg/kg), and the optimum dose was supposed to be about 10 mg/kg when administered PO, consecutively. These doses were almost the same as those for the treatment of tumors in the mice mentioned above. A protein-bound polysaccharide, EA6, was also isolated from fruit bodies of F. velutipes. Treatment with EA6 after the surgery remarkably inhibited growth of the rechallenged Meth-A solid tumor, and the effect was mediated by CD4+ T cells. Furthermore, EA6 augmented the humoral immunity, cellular immunity, and IL-2 production against Meth-A tumor antigen after surgery.
-
Wasser Solomon P., Current findings, future trends, and unsolved problems in studies of medicinal mushrooms, Applied Microbiology and Biotechnology, 89, 5, 2011. Crossref
-
De Silva Dilani D., Rapior Sylvie, Fons Françoise, Bahkali Ali H., Hyde Kevin D., Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action, Fungal Diversity, 55, 1, 2012. Crossref
-
Tang Calyn, Hoo Pearl Ching-Xin, Tan Loh Teng-Hern, Pusparajah Priyia, Khan Tahir Mehmood, Lee Learn-Han, Goh Bey-Hing, Chan Kok-Gan, Golden Needle Mushroom: A Culinary Medicine with Evidenced-Based Biological Activities and Health Promoting Properties, Frontiers in Pharmacology, 7, 2016. Crossref
-
Wasser Solomon P., Medicinal Properties and Clinical Effects of Medicinal Mushrooms, in Edible and Medicinal Mushrooms, 2017. Crossref
-
Vetchinkina Elena, Fomin Alexander, Navolokin Nikita, Shirokov Alexander, Proteins and polysaccharides from vegetative mycelium of medicinal basidiomycete Lentinus edodes display cytotoxicity towards human and animal cancer cell lines, International Journal of Biological Macromolecules, 195, 2022. Crossref